Recent Press Releases

Amgen To Present At The Goldman Sachs Global Healthcare Conference

THOUSAND OAKS, Calif., June 8, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Goldman Sac

Mylan Launches First Bioequivalent Alternative to Combination Asthma Therapy Seretide(R) Evohaler(R) (Salmeterol Xinafoate/Fluticasone Propionate) Under the Brand Name Sirdupla(TM) in the UK

Mylan becomes the first company to market a generic version of the UK's number one prescribed long-acting beta2-agonist + inhaled corticosteroid pressurized metered-dose inhaler asthma...

Sobi Board of Directors terminates discussions regarding non-binding proposal

Sobi Board of Directors terminates discussions regarding non-binding proposal 2015-06-08 -- On 27 April 2015 the Board of Swedish Orphan Biovitrum AB (publ) (Sobi) confirmed that it had received a...

Study: Once-Weekly Trulicity™ (dulaglutide) Provides Greater Blood Sugar Reduction Compared to Once-Daily Victoza® (liraglutide) in Japanese Patients after 52 weeks

Data to be presented at 75th American Diabetes Association Scientific Sessions®

INDIANAPOLIS, June 6, 2015<

Basal Insulin Peglispro Studies Demonstrate Superiority to Insulin Glargine Across Multiple Measures in People with Type 1 Diabetes

Phase III Data Presented at the 2015 American Diabetes Association Scientific Sessions®

INDIANAPOLIS, June

Lilly's Basal Insulin Peglispro Shows Superiority to Insulin Glargine in Reducing HbA1c in People with Type 2 Diabetes

Data from Phase III Clinical Trial Program Presented at the 2015 American Diabetes Association Scientific Sessions®

INDIANAPOLIS,

Orexigen and Takeda File Lawsuit Against Actavis for Infringement of Contrave® Patents

SAN DIEGO, June 5, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that it and its North American partner, Takeda Pharmaceuticals, have filed a lawsuit in the U.S....

NICE publishes draft guidance for two prostate cancer treatments

NICE publishes draft guidance for two prostate cancer treatments The National Institute for Health and Care Excellence (NICE) has launched public consultations on draft recommendations for two...

Lilly commits 780,000 additional vials of insulin to Life for a Child

Renewed commitment will help more children in impoverished communities

INDIANAPOLIS, June 4, 2015 /P

Lilly to Present Pivotal Phase 3 Study Results for Investigational Psoriasis Treatment at 23rd World Congress of Dermatology

INDIANAPOLIS, June 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will showcase results from three

Universal Health Services, Inc. To Present At Goldman Sachs 36th Annual Global Healthcare Conference

KING OF PRUSSIA, Pa., June 3, 2015 /PRNewswire/ -- Universal Health Services, Inc.

Roche receives FDA clearance for the cobas® HSV 1 and 2 Test for the detection of herpes simplex virus

New test expands menu for sexually transmitted infections testing on the cobas® 4800 System

PLEASANTON, Calif.,

Ardelyx Regains Worldwide Development and Commercialization Rights for Its Late-Stage Development Candidate, Tenapanor, and Related Portfolio of NHE3 Compounds

Ardelyx to Initiate a Phase 3 Clinical Program in IBS-C Patients in the Fourth Quarter of 2015

FREMONT, Calif.,

Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares

Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares DUBLIN, June 2, 2015 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) (the...

Endo International plc Announces Proposed Public Offering of $1.75 Billion of Ordinary Shares

DUBLIN, June 2, 2015 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) (TSX: ENL) (the "Company" or "Endo") announced today that it has commenced an underwritten public...

Actavis Affirms Commitment To Advancing Antibiotic Stewardship At White House Forum

- Actavis Commitment Extends to Fostering Collaborative Research Efforts, Gathering Unique Epidemiological Information and Generating Real-World Data to Demonstrate the Effects of Stewardship on P

POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO

CHAPEL HILL, N.C.--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced that John R. Plachetka, Pharm.D., its founder, Chairman,...

Perrigo To Acquire Portfolio Of Leading OTC Brands From GSK

-- Portfolio includes well-established European brands in the areas of nicotine replacement therapy, cold and flu, and cold sore management -- Demonstrates Perrigo's unique ability to maximize...

Actavis And Perrigo Receive FDA Approval Of Guaifenesin/Pseudoephedrine, The Store Brand Equivalent To Mucinex(R) D Tablets

DUBLIN, June 2, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) and its partner Perrigo Company plc (NYSE: PRGO; TASE) announced today that Actavis has received U.S. Food and Drug Administration...